LAURAN NEERGAARD and DANICA KIRKA, Associated Press
Britain became the first country in the world to authorize a rigorously tested COVID-19 vaccine Wednesday and could be dispensing shots within days — a historic step toward eventually ending the scourge that has killed more than 1.4 million people around the globe.
In giving the go-ahead for emergency use of the vaccine developed by American drugmaker Pfizer and Germany’s BioNTech, Britain vaulted past the United States by at least a week. The U.S. Food and Drug Administration is not scheduled to consider the vaccine until Dec. 10.
“This is a day to remember, frankly, in a year to forget,” British Health Secretary Matt Hancock said.
The announcement sets the stage for the biggest vaccination campaign in British history and came just ahead of what experts are warning will be a long, dark winter, with the coronavirus surging to epic levels in the U.S. and Europe and putting pressure on hospitals and businesses.
Officials cautioned that several tough months still lie ahead even in Britain, given the monumental scale of the operation needed to vaccinate large swaths of the population. Because of the limited initial supply, the first shots will be reserved for those most in danger, namely nursing home patients, the elderly and health care workers.
Britain’s Medicines and Healthcare Products Regulatory Agency recommended the vaccine after clinical trials showed it was 95% effective and offered significant protection for older people. The vaccine remains experimental while final testing is done.
“This is an unprecedented piece of science,” given that the vaccine was authorized less than a year after the virus was discovered, said David Harper, senior consulting fellow in global health at the Chatham House think tank.
Prime Minister Boris Johnson declared that the “searchlights of science” had picked out the “invisible enemy.” He said that in developing the vaccine, scientists had performed “biological ju jitsu” by turning the virus on itself.
Other countries aren’t far behind: Regulators not only in the U.S. but in the European Union and Canada also are vetting the Pfizer vaccine along with a shot made by Moderna Inc. British and Canadian regulators are also considering a vaccine made by AstraZeneca and Oxford University.
Amid growing concern in the U.S. that Americans will greet vaccines with skepticism, U.S. Health and Human Services Secretary Alex Azar said Britain’s decision “should give Americans additional confidence in the quality of such a vaccine.”
Hancock said Britain will begin receiving the first shipment of 800,000 doses from Belgium within days, and people will start getting the shots as soon as it arrives. Two doses three weeks apart are required. The country expects to receive millions of doses by the end of this year, Hancock said, though the exact number will depend on how fast it can be manufactured and checked for quality.
BioNTech, which owns the vaccine, said it has so far signed deals to supply 570 million doses worldwide in 2021, with options to deliver 600 million more. It hopes to supply at least 1.3 billion in 2021.
That is only a fraction of what will be needed as public health officials try to vaccinate much of the world’s population. Experts have said several vaccines will be required to quickly end the pandemic.
In Britain, the first shots will go to nursing home patients and those who care for them, followed by everyone over 80 and health care workers. From there, the program will be expanded as the supply increases, with the vaccine offered roughly on the basis of age groups, starting with the oldest people.
Despite the speed with which they approved the vaccine, and the intense political pressure surrounding the worldwide race to solve the crisis, British regulators insisted “no corners have been cut” during the review process.
The MHRA made its recommendation following a so-called rolling review that allowed it to assess information about the vaccine as it became available, starting back in October.
“The safety of the public will always come first,” said Dr. June Raine, chief executive of the agency. “And I emphasize again that this recommendation has only been given by the MHRA following the most rigorous scientific assessment of every piece of data.”
Getting that message to the public will be critical if any vaccination program is to be successful. Some people are worried about getting any vaccine, never mind a new one.
“But I think once they understand and see everyone else having it without hesitation, I think you’ll find that people will go and have it,” Jacqueline Roubians, a 76-year-old retired nurse, said at Brixton Market in London. “People are dying of COVID, so you make that decision: Do you want to die or do you want the vaccine?”
In addition to the huge logistical challenges of distributing the vaccines, the Pfizer-BioNTech one must be stored and shipped at ultra-cold temperatures of around minus 70 degrees Celsius (minus 94 degrees Fahrenheit).
Pfizer said that it has developed shipping containers that use dry ice and that GPS-enabled sensors will allow the company to track each shipment and ensure it stays cold.
Every country has different rules for determining when an experimental vaccine is safe and effective enough to use. China and Russia have offered different vaccines to their citizens before they had gone through large-scale, late-stage testing.
Hours after Britain’s announcement, Russian President Vladimir Putin, not to be outdone, ordered the start of a large-scale COVID-19 vaccination campaign by late next week, with doctors and teachers to be first in line to receive the Sputnik V shot, whose name was inspired by the 1957 satellite that was one of Moscow’s proudest technical achievements.
The Russian vaccine won regulatory approval in August but has yet to complete advanced studies of its effectiveness and safety. Health Minister Mikhail Murashko said more than 100,000 people in Russia have been given the shots.
The vaccine made by Pfizer and BioNTech was tested in tens of thousands of people, and the makers reported no serious side effects. Still to be determined is whether the shots protect against people spreading the virus without having symptoms. Another question is how long protection lasts.
The vaccine also has been tested in only a small number of children, none younger than 12, and there’s no information on its effects in pregnant women.
Neergaard reported from Alexandria, Virginia. Associated Press writers Frank Jordans in Berlin and Lawless, Pan Pylas and Jo Kearney in London contributed